Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAnne‐Ségolène CottereauLCLoïc ChartierCBConnie Lee Batlevi

Discussion

Loading...

Member takes

Overview

This analysis demonstrates the prognostic value of FDG PET metrics in diffuse large B-cell lymphoma, suggesting significant implications for treatment strategies.

Key Points

  • Evaluate the prognostic value of FDG PET-derived markers in patients with diffuse large B-cell lymphoma treated with Polatuzumab vedotin.
  • Baseline FDG-PET/CT scans reviewed to assess total metabolic tumor volume using a standardized uptake value threshold.
  • Interim and end-of-treatment PET responses assessed according to Lugano criteria.
  • Prognostic metrics analyzed using Kaplan–Meier and Cox proportional hazards methods.
  • High baseline TMTV and TLG were strong predictors of progression-free survival across treatment arms.
  • Metabolic response at end-of-treatment was key in differentiating relapse risk and overall survival.
  • In patients achieving complete metabolic response, significant survival benefits were noted with Pola-R-CHP compared to R-CHOP.

Cite This Study

Cottereau et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db0ahttps://doi.org/10.1182/blood-2025-5329
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pola-R-CHP in previously untreated low-risk (IPI 0-1) DLBCL: A nationwide multicenter retrospective study in China2025
  2. 2Pola-R-CHP in newly diagnosed primary mediastinal B-cell lymphoma:high efficacy and tolerability2025
  3. 3Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data2025
  4. 4Real-world comparative outcomes of pola-R-CHP versus R-CHOP in patients with diffuse large B-cell lymphoma2025 · 1 citations
  5. 5Polatuzumab-vedotin in large diffuse B-cell lymphoma: A multicenter observational study from Latin America (2020–2024)2025